









Markets
/
Stocks
/
nasdaq-eols
/

Evolus Inc

EOLS

4.500USD

+0.090+2.04%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

291.45MMarket Cap

LossP/E TTM



Evolus Inc

4.500

+0.090+2.04%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Evolus Inc

Currency: USD Updated: 2026-02-06

Key Insights

Evolus Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 52 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.67.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Evolus Inc's Score

Industry at a Glance

Industry Ranking

52 / 159

Overall Ranking

152 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Evolus Inc Highlights

StrengthsRisks

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 79.17% year-on-year.

Overvalued

The company’s latest PE is -4.95, at a high 3-year percentile range.

Held by PRFDX

Star Investor PRFDX holds 27.54K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.68.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

14.667

Target Price

+232.58%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Evolus Inc is 7.92, ranking 92 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 68.97M, representing a year-over-year increase of 12.90%, while its net profit experienced a year-over-year increase of 17.91%.

Score

Industry at a Glance

Previous score

7.92

Change



Financials

5.32

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.94

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.92

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.43

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Evolus Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Evolus Inc is 8.03, ranking 32 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -4.95, which is -2.00% below the recent high of -4.85 and -290.24% above the recent low of -19.32.

Score

Industry at a Glance

Previous score

8.03

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 52/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Evolus Inc is 8.57, ranking 25 out of 159 in the Pharmaceuticals industry. The average price target is 19.50, with a high of 20.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

8.57

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

14.667

Target Price

+232.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Evolus Inc

EOLS

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Evolus Inc is 6.38, ranking 129 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 5.46 and the support level at 3.98, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.28

Change

0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.020

Neutral

RSI(14)

31.558

Neutral

STOCH(KDJ)(9,3,3)

14.787

Oversold

ATR(14)

0.251

Low Volatility

CCI(14)

-124.154

Sell

Williams %R

88.623

Oversold

TRIX(12,20)

-1.268

Sell

StochRSI(14)

39.702

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

4.622

Sell

MA10

4.703

Sell

MA20

4.968

Sell

MA50

6.055

Sell

MA100

6.316

Sell

MA200

7.695

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Evolus Inc is 7.00, ranking 44 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 89.22%, representing a quarter-over-quarter decrease of 1.08%. The largest institutional shareholder is The Vanguard, holding a total of 3.34M shares, representing 5.16% of shares outstanding, with 3.10% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Nantahala Capital Management, LLC

5.73M

+36.42%

Tang Capital Management, LLC

5.49M

+9.82%

Lynch (Timothy Patrick)

5.13M

+25.38%

Caligan Partners, LP

4.14M

+23.85%

BlackRock Institutional Trust Company, N.A.

3.99M

+9.30%

The Vanguard Group, Inc.

Star Investors

3.42M

+3.35%

Frazier Life Sciences Management, L.P.

2.63M

+8.01%

Medy Tox Inc

2.14M

-36.82%

Millennium Management LLC

1.86M

+25.32%

Stonepine Capital Management, LLC

1.54M

+67.64%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Evolus Inc is 5.30, ranking 70 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.02. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.